Radiolabeled Antibody Therapy
The Department of Radiation Oncology at Cleveland Clinic is also at the cutting edge of research in pioneering the use of several specialized lymphoma radiotherapy treatment techniques. For certain types of indolent lymphomas, the use of radio-labeled antibodies as a form of experimental "systemic radiotherapy" is under evaluation. Several different antibodies bound to several different isotopes have been used in clinical trials at Cleveland Clinic.
The advantage of this approach, as opposed to the brachytherapy programs, is that the "targeted radiotherapy" can be injected into the circulation and allowed to localize simultaneously in many different sites of disease involvement. Although the exact level of clinical effectiveness for this sort of radiotherapy treatment will vary depending on the case, 60-80% or more of patients who receive this sort of radiotherapy treatment will demonstrate a good clinical response even for fairly advanced cases, with a 20-40% complete response rate.
In the US there are currently 2 FDA-cleared radiolabeled antibodies that are in use at CCF and elsewhere: Y-90 ibritumomab tiuxetan ("Zevalin") and I-131-tositumomab (“Bexxar”). Both are approved for the treatment of relapsed refractory and transformed indolent B cell NHL. Both have also shown dramatic effects in frontline treatment for indolent lymphoma and are currently seeking approval for this "radio-immunotherapy" indication in the US. This approval was granted in Europe in 2008.
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.